Dengue Literature Review

Garcia2010 - Asymptomatic Dengue FcγRIIa Polymorphism

4 min read

Garcia2010 - Asymptomatic Dengue FcγRIIa Polymorphism

Full citation: García G, Sierra B, Pérez AB, Aguirre E, Rosado I, Gonzalez N, Izquierdo A, Pupo M, Ruiz D, Díaz D, Sánchez L, Marcheco B, Hirayama K, Guzmán MG. Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcγRIIa polymorphism. American Journal of Tropical Medicine and Hygiene 82(6), 2010: 1153–1156. https://doi.org/10.4269/ajtmh.2010.09-0353

Raw file: [[raw/garcia2010.pdf]]

Summary

This study used the same Cuban adult cohort as Garcia2009 - Long-term Clinical Symptoms Post-Dengue — 97 symptomatic patients (68 DF, 29 DHF/DSS) and 42 asymptomatic individuals from the 2006 DENV-4 Havana epidemic — to compare FcγRIIa genotype frequencies across the three clinical outcome groups. The central question was whether the FcγRIIa polymorphism predisposes individuals not only to severe disease (as suggested by a prior Vietnamese study) but to symptomatic infection itself, relative to asymptomatic infection.

The HH genotype was present in 51.5% of DHF cases, 39.4% of DF cases, but only 9.1% of asymptomatic individuals (p = 0.008). Conversely, the RR genotype was significantly enriched in the asymptomatic group and was independently protective against DHF (OR = 0.09, p = 0.01). This is the first report linking FcγRIIa-RR to protection against symptomatic dengue infection, not just severe disease.

The authors also discuss the population-level implications: Havana’s FcγRIIa distribution (55% RR, 32% HR, 13% HH) differs markedly from Asian populations (6–10% RR), which may partly explain why severe dengue is more prevalent in Asia. A noted controversy — Bruhns et al. (2009) found IgG1 binds less efficiently to FcγRIIa-R than to FcγRIIa-H, directly challenging the assumed protective mechanism.

Study Design

  • Type: Case-control genetic association study
  • Sample size: 139 individuals: 68 DF, 29 DHF/DSS, 42 asymptomatic (subclinical)
  • Setting: Instituto Pedro Kourí (IPK), Havana, Cuba; same cohort as Garcia2009, sampled during/after 2006 DENV-4 epidemic
  • Population: Adults aged 21–81 years (mean ~46); 67 female, 30 male; all confirmed DENV-4 infection by IgM; asymptomatic group identified by IgG titer ≥1,280 in absence of symptoms

Key Findings

  • HH131 genotype frequency: DHF 51.5%, DF 39.4%, asymptomatic 9.1% — significantly higher in clinical groups (p = 0.008)
  • HH vs HR+RR: OR for DHF = 10.56 (95% CI 2.33–54.64, p = 0.00018); OR for DF = 4.33 (95% CI 1.08–20.10, p = 0.018) — both vs asymptomatic group
  • RR131 associated with protection against DHF: OR = 0.09, p = 0.01
  • H allele frequency: DHF 62.1%, DF 50.0%, asymptomatic 34.5% (χ² = 10.92, p = 0.004)
  • No significant allele frequency difference between DF and DHF groups alone (χ² = 0.59, p = 0.44); asymptomatic group inclusion drives the association
  • Havana population baseline: 55% RR, 32% HR, 13% HH — compared to Asian populations at only 6–10% RR
  • Population difference hypothesised to partly explain higher severe dengue rates in Asia vs Cuba

Methods Used

Entities Mentioned

Concepts Addressed

Relevance & Notes

This paper is the direct companion to Garcia2009 - Long-term Clinical Symptoms Post-Dengue — same cohort, same IPK group, same 2006 epidemic. Together they establish a consistent picture: HH genotype is a risk factor both for symptomatic/severe acute disease (this paper) and for persistent post-dengue sequelae (Garcia2009), while RR is protective at both ends.

The Bruhns et al. (2009) contradiction is significant: if IgG1 actually binds more efficiently to FcγRIIa-H than -R, the classic ADE-based explanation for HH risk may need revision. The authors acknowledge this cannot be resolved without further studies using polyclonal (not monoclonal) anti-DENV IgG1/3 complexes specifically.

Limitation: only DENV-4 infected individuals studied; generalisability to other serotypes untested. Sample size for DHF group (n = 29) is modest for genetic association work.

Questions Raised

  • Does the FcγRIIa-RR protective association hold for DENV-1, -2, and -3?
  • What is the actual binding affinity of polyclonal DENV IgG1/3 complexes for RR vs HH variants — does the Bruhns finding hold under infection conditions?
  • Do other genetic polymorphisms (HLA, vitamin D receptor, CD209) interact with FcγRIIa genotype to modify disease outcome?
  • Does the population-level RR frequency difference between Cuba and Asia predict aggregate DHF burden at the population level?

Graph View

Backlinks